Clinical Trial Update: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study comparing Linvoseltamab as monotherapy or in combination with Carfilzomib versus standard-of-care regimens …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Linvoseltamab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 3 | Status: RECRUITING